High-yield map
Key points before the detail
- 01
Grade = microscopic aggressiveness; stage = anatomical extent.
- 02
T, N and M definitions vary by tumour site, so never transplant one organ’s size thresholds to another.
- 03
cTNM is based on pretreatment clinical information; pTNM incorporates pathological examination of resection material where applicable.
- 04
UICC TNM 9 was published in 2025 and recommended to take effect on 1 January 2026; UK site-specific datasets should be checked for the applicable version.
Grade and stage answer different questions
| Concept | Question answered | Typical inputs |
|---|---|---|
| Grade | How aggressive does the tumour look microscopically? | Differentiation, architecture, mitoses and tumour-specific microscopic features. |
| Stage | How far has the cancer spread anatomically? | Primary tumour extent, regional nodes and distant metastasis, plus organ-specific staging rules. |
The TNM framework
| Component | Meaning |
|---|---|
| T | Primary tumour extent; criteria are site-specific and may depend on size, depth or invasion of named structures. |
| N | Regional lymph-node involvement using organ-specific nodal definitions. |
| M | Presence or absence of distant metastatic spread using the applicable classification. |
Clinical and pathological staging
Clinical TNM (cTNM) uses the information available before definitive treatment, including examination, imaging, endoscopy and biopsy. Pathological TNM (pTNM) uses pathological assessment of resection material where the site-specific rules allow it. Additional prefixes such as y and r communicate staging after neoadjuvant treatment or at recurrence. “X” means a category cannot be assessed; “0” means no evidence in that category.
- A stage group is derived from an organ-specific combination of T, N and M; it is not simply another name for T.
- Post-neoadjuvant staging should be labelled so that treated disease is not confused with untreated pathological stage.
- Historic systems such as Dukes can help interpret older literature but should not replace current, version-labelled TNM in contemporary reporting.
Current 2026 context: UICC TNM 9
The Union for International Cancer Control published the 9th edition of TNM in 2025 and recommends implementation from 1 January 2026. The edition includes site-specific revisions rather than one universal change. The Royal College of Pathologists has been publishing updated TNM 9 appendices for UK cancer datasets, including colorectal and multiple other tumour sites.
Why staging accuracy matters
- Communicates disease extent consistently across multidisciplinary teams.
- Supports prognosis and treatment planning.
- Allows meaningful comparison of outcomes and research cohorts.
- Prevents false precision: using an obsolete edition or wrong organ-specific rule can change stage and therefore clinical interpretation.
Active recall
Close the notes and answer these
Try each question from memory before revealing the answer. These public prompts are a small preview of the integrated retrieval system inside SurgAtlas.
01What is the simplest distinction between grade and stage?
Grade describes microscopic aggressiveness; stage describes anatomical extent.
02What is the difference between cTNM and pTNM?
cTNM is based on pretreatment clinical information; pTNM incorporates pathological examination of surgical material according to site-specific rules.
03Which TNM edition is current in the 2026 SurgAtlas lesson?
UICC TNM 9, published in 2025 and recommended by UICC to take effect from 1 January 2026.
Sources & editorial basis
References & editorial basis
- SurgAtlas production chapter — Staging, Grading and TNM Classification. Primary source for this public lesson. The public teaching is a condensed, source-derived version of the corresponding production pathology chapter.
- UICC — TNM Classification of Malignant Tumours, 9th edition. UICC states that the 9th edition was published in 2025 and recommends it take effect from 1 January 2026. Source ↗
- Royal College of Pathologists — Cancer datasets and tissue pathways. Current UK site-specific cancer datasets and updated TNM 9 appendices. Source ↗
This lesson is derived from the corresponding SurgAtlas production teaching material. Where the source makes current management or guideline claims, the public lesson uses the cited contemporary guidance. It is written for education and examination preparation, not as patient-specific clinical advice.
Editorial details
Medical Doctor (MD) · MRCS Part A · Physician · Surgical Educator
SurgAtlas is an educational resource. For patient care, verify current national guidance, local antimicrobial and transfusion policies, specialty pathways and individual patient factors.
Continue in SurgAtlas
Turn reading into retrieval.
Use the full learning workspace for chapter progress, integrated questions, review scheduling and exam-focused study tools. Free accounts do not include recurring AI usage.